These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26059422)

  • 1. Analysis of clinical trials with biologics using dose-time-response models.
    Lange MR; Schmidli H
    Stat Med; 2015 Sep; 34(22):3017-28. PubMed ID: 26059422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal design of clinical trials with biologics using dose-time-response models.
    Lange MR; Schmidli H
    Stat Med; 2014 Dec; 33(30):5249-64. PubMed ID: 25209423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bayesian bias correction method of the first-order approximation of nonlinear mixed-effects models for population pharmacokinetics.
    Funatogawa T; Funatogawa I
    J Biopharm Stat; 2007; 17(3):381-92. PubMed ID: 17479388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals.
    Tibbitts J; Cavagnaro JA; Haller CA; Marafino B; Andrews PA; Sullivan JT
    Regul Toxicol Pharmacol; 2010 Nov; 58(2):243-51. PubMed ID: 20558225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional uniform priors for nonlinear modeling.
    Bornkamp B
    Biometrics; 2012 Sep; 68(3):893-901. PubMed ID: 22845801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistics and the relationship of clinical research to clinical practice.
    Khuder SA; Kahaleh B
    J Rheumatol; 2009 Feb; 36(2):219-20. PubMed ID: 19208555
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying physiological and biochemical concepts to optimize biological drug development.
    Lowe PJ
    Clin Pharmacol Ther; 2010 Apr; 87(4):492-6. PubMed ID: 20147897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indications for and use of biologics in early rheumatoid arthritis based on the evidence].
    Takeuchi T
    Nihon Rinsho; 2009 May; 67(5):1043-9. PubMed ID: 19432131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic-pharmacodynamic modeling of biological agents: when modeling meets reality.
    Mould DR; Frame B
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):91S-100S. PubMed ID: 20881222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian approach for dose-escalation in a Phase I clinical trial incorporating pharmacodynamic endpoints.
    Whitehead J; Zhou Y; Hampson L; Ledent E; Pereira A
    J Biopharm Stat; 2007; 17(6):1117-29. PubMed ID: 18027220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing dose-region profile of drug efficacy: a multiregional trial strategy.
    Chen YH; Wang M
    J Biopharm Stat; 2012 Sep; 22(5):894-902. PubMed ID: 22946938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confidence bounds for nonlinear dose-response relationships.
    Baayen C; Hougaard P
    Stat Med; 2015 Nov; 34(27):3546-62. PubMed ID: 26112765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved designs for dose escalation studies using pharmacokinetic measurements.
    Piantadosi S; Liu G
    Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing drug additivity based on monotherapies.
    Yang H; Novick SJ; Zhao W
    Pharm Stat; 2015; 14(4):332-40. PubMed ID: 25962689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis.
    Nixon RM; Bansback N; Stevens JW; Brennan A; Madan J
    Pharm Stat; 2009; 8(2):150-62. PubMed ID: 18942777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A flexible Bayesian approach for modeling monotonic dose-response relationships in drug development trials.
    Ohlssen D; Racine A
    J Biopharm Stat; 2015; 25(1):137-56. PubMed ID: 24836192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
    Wang DD; Zhang S; Zhao H; Men AY; Parivar K
    J Clin Pharmacol; 2009 Sep; 49(9):1012-24. PubMed ID: 19620385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.